Literature DB >> 27603300

Transient remission of nonalcoholic fatty liver disease decreases the risk of incident type 2 diabetes mellitus in Japanese men.

Takuya Fukuda1, Masahide Hamaguchi, Takao Kojima, Kazuteru Mitsuhashi, Yoshitaka Hashimoto, Akihiro Ohbora, Takahiro Kato, Naoto Nakamura, Michiaki Fukui.   

Abstract

INTRODUCTION: It is unclear how the transient remission of nonalcoholic fatty liver disease (NAFLD) affects incident type 2 diabetes mellitus (T2DM). Here, we sought to determine the effect of the transient remission of NAFLD on incident T2DM in Japanese men.
MATERIALS AND METHODS: We used a population-based health check-up program. The primary outcome was set as incident T2DM. We divided the participants who showed NAFLD at the time of enrollment into three groups according to their clinical course of NAFLD: the Regression group, in which the participants showed a regression of NAFLD and no relapse during the follow-up period; the Transient Remission group, in which participants achieved a transient remission of NAFLD, but had a relapse of NAFLD; and the Persistent group, in which participants showed NAFLD throughout the follow-up. The Never group of participants who did not show NAFLD throughout the follow-up served as a reference.
RESULTS: The incidence rates of T2DM in the Never group, the Regression group, the Transient Remission group, and the Persistent group were 4.7% (62/1306), 9.2% (14/153), 18.0% (25/139), and 35.1% (120/342), respectively. In a multivariate Cox regression analysis with covariates, the adjusted hazard ratios for incident T2DM compared with the Never group were as follows: Regression group: 1.08 [95% confidence interval (CI) 0.53-2.04, P=0.81], Transient Remission group: 2.12 (95% CI 1.22-3.57, P<0.01), and Persistent group: 3.44 (95% CI 2.29-5.21, P<0.001). The adjusted hazard ratio of the Transient Remission group was significantly lower than that of the Persistent group (P<0.05).
CONCLUSION: Transient remission of NAFLD significantly decreased the risk of developing T2DM.

Entities:  

Mesh:

Year:  2016        PMID: 27603300     DOI: 10.1097/MEG.0000000000000736

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  12 in total

1.  The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis.

Authors:  Yuankai Wu; Qi Zheng; Biyao Zou; Yee Hui Yeo; Xiaohe Li; Jie Li; Xiaoyu Xie; Yuemin Feng; Christopher Donald Stave; Qiang Zhu; Ramsey Cheung; Mindie H Nguyen
Journal:  Hepatol Int       Date:  2020-03-04       Impact factor: 6.047

2.  Fatty liver as a risk factor for progression from metabolically healthy to metabolically abnormal in non-overweight individuals.

Authors:  Yoshitaka Hashimoto; Masahide Hamaguchi; Takuya Fukuda; Akihiro Ohbora; Takao Kojima; Michiaki Fukui
Journal:  Endocrine       Date:  2017-05-16       Impact factor: 3.633

3.  Early maternal circulating alkaline phosphatase with subsequent gestational diabetes mellitus and glucose regulation: a prospective cohort study in China.

Authors:  Ting Xiong; Chunrong Zhong; Guoqiang Sun; Xuezhen Zhou; Renjuan Chen; Qian Li; Yuanjue Wu; Qin Gao; Li Huang; Xingwen Hu; Mei Xiao; Xuefeng Yang; Liping Hao; Nianhong Yang
Journal:  Endocrine       Date:  2019-05-21       Impact factor: 3.633

Review 4.  NADPH Oxidases Connecting Fatty Liver Disease, Insulin Resistance and Type 2 Diabetes: Current Knowledge and Therapeutic Outlook.

Authors:  Alberto Nascè; Karim Gariani; François R Jornayvaz; Ildiko Szanto
Journal:  Antioxidants (Basel)       Date:  2022-06-09

Review 5.  The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments.

Authors:  Giovanni Targher; Kathleen E Corey; Christopher D Byrne; Michael Roden
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-05-10       Impact factor: 46.802

6.  Bidirectional association between nonalcoholic fatty liver disease and type 2 diabetes in Chinese population: Evidence from the Dongfeng-Tongji cohort study.

Authors:  Yaru Li; Jing Wang; Yuhan Tang; Xu Han; Bing Liu; Hua Hu; Xiulou Li; Kun Yang; Jing Yuan; Xiaoping Miao; Ping Yao; Sheng Wei; Youjie Wang; Yuan Liang; Xiaomin Zhang; Huan Guo; An Pan; Handong Yang; Frank B Hu; Tangchun Wu; Meian He
Journal:  PLoS One       Date:  2017-03-28       Impact factor: 3.240

Review 7.  Nonalcoholic fatty liver disease: Evolving paradigms.

Authors:  Amedeo Lonardo; Fabio Nascimbeni; Mauro Maurantonio; Alessandra Marrazzo; Luca Rinaldi; Luigi Elio Adinolfi
Journal:  World J Gastroenterol       Date:  2017-09-28       Impact factor: 5.742

8.  Non-Alcoholic Fatty Liver Disease Is an Independent Risk Factor for LDL Cholesterol Target Level.

Authors:  Jun-Hyuk Lee; Hye Sun Lee; A-Ra Cho; Yong-Jae Lee; Yu-Jin Kwon
Journal:  Int J Environ Res Public Health       Date:  2021-03-26       Impact factor: 3.390

9.  Reduction of Fat to Muscle Mass Ratio Is Associated with Improvement of Liver Stiffness in Diabetic Patients with Non-Alcoholic Fatty Liver Disease.

Authors:  Takafumi Osaka; Yoshitaka Hashimoto; Takuro Okamura; Takuya Fukuda; Masahiro Yamazaki; Masahide Hamaguchi; Michiaki Fukui
Journal:  J Clin Med       Date:  2019-12-09       Impact factor: 4.241

10.  Serum levels of mac-2 binding protein are associated with diabetic microangiopathy and macroangiopathy in people with type 2 diabetes.

Authors:  Yoshitaka Hashimoto; Masahide Hamaguchi; Ayumi Kaji; Ryosuke Sakai; Noriyuki Kitagawa; Michiaki Fukui
Journal:  BMJ Open Diabetes Res Care       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.